Compare PMCB & ADIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PMCB | ADIL |
|---|---|---|
| Founded | 1996 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.3M | 7.3M |
| IPO Year | 2001 | 2017 |
| Metric | PMCB | ADIL |
|---|---|---|
| Price | $0.55 | $4.27 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $37.50 |
| AVG Volume (30 Days) | ★ 125.6K | 56.4K |
| Earning Date | 03-17-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.53 | $0.13 |
| 52 Week High | $1.51 | $5.17 |
| Indicator | PMCB | ADIL |
|---|---|---|
| Relative Strength Index (RSI) | 35.67 | 69.55 |
| Support Level | $0.55 | $2.38 |
| Resistance Level | $0.77 | $5.08 |
| Average True Range (ATR) | 0.04 | 0.45 |
| MACD | 0.00 | 0.09 |
| Stochastic Oscillator | 31.02 | 74.83 |
PharmaCyte Biotech Inc is a biotechnology company focused on developing cellular therapies for cancer based on its proprietary cellulose-based live cell encapsulation technology, Cell-in-a-Box. The technology is intended to be used as a platform for therapies for several types of cancer, including locally advanced, inoperable pancreatic cancer (LAPC). The current generation of the Company's product candidate is CypCaps. The Company is preparing to commercialize cellular therapies for cancer and advance clinical research and development, including a clinical trial in LAPC using encapsulated live cells. Its candidate therapy involves encapsulating genetically engineered human cells that convert an inactive chemotherapy drug into its active, cancer-killing form.
Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its investigational new drug candidate, AD04, is being developed as a therapeutic agent for the treatment of alcohol use disorder. The company operates as one operating segment with a focus on drug development for addiction and related disorders.